Abstract Number: 1303 • 2012 ACR/ARHP Annual Meeting
Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone
Background/Purpose: Effective treatment of rheumatoid arthritis (RA) patients (pts) aims to suppress inflammation, preserve physical function, and prevent structural damage, which together represent the hallmarks…Abstract Number: 369 • 2012 ACR/ARHP Annual Meeting
Differences in Short-Term Radiographic Progression Following Early Response to Adalimumab Plus Methotrexate Vs. Methotrexate Alone
Background/Purpose: To prevent disease progression, treat-to-target recommendations for rheumatoid arthritis (RA) include the evaluation and adjustment of drug therapy at least every 3 months until…Abstract Number: 1304 • 2012 ACR/ARHP Annual Meeting
Long-Term Use of Adalimumab As Monotherapy Following Attainment of Low Disease Activity with Adalimumab Plus Methotrexate
Background/Purpose: There has been increased interest in understanding whether biologics can be safely withdrawn from patients (pts) receiving combination therapy with MTX once a clinical…Abstract Number: 185 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Tumour Necrosis Factor Antagonists for Patients with Behçet’s Disease with Uveitis As Main Involvement
Background/Purpose: To assess the long-term efficacy and safety of tumour necrosis factor (TNF) antagonists (infliximab [IFX], adalimumab [ADA] and golimumab) for the treatment of patients…
- « Previous Page
- 1
- …
- 15
- 16
- 17